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OBJECTIVE — To determine whether serum uric acid predicts incident type 2 diabetes by
glucose tolerance status in older community-dwelling adults.
RESEARCH DESIGN AND METHODS — Participants without diabetes at baseline
were evaluated for incident type 2 diabetes 13 years later. Baseline glucose tolerance status was
deﬁned as normoglycemia, impaired fasting glucose, and impaired postchallenge glucose
tolerance.
RESULTS — Atotalof566participantswereincluded(meanage63.38.6years;41%men).
Regression models adjusted for age, sex, BMI, diuretic use, and estimated glomerular ﬁltration
rate showed that for each 1 mg/dl increment in uric acid levels, incident type 2 diabetes risk
increased by 60%. When analyses were stratiﬁed by glucose status, uric acid levels indepen-
dently predicted incident type 2 diabetes among participants who had impaired fasting glucose
(odds ratio 1.75, 95% CI 1.1–2.9, P  0.02).
CONCLUSIONS — Uric acid may be a useful predictor of type 2 diabetes in older adults
with impaired fasting glucose.
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ncreased levels of serum uric acid have
been associated with insulin resistance
(1) and with established type 2 diabe-
tes (2). Previous studies demonstrated
that uric acid is an independent predictor
ofincidenttype2diabetesingeneralpop-
ulations (3,4), but whether uric acid pre-
dicts incident type 2 diabetes in
individuals who have abnormal glucose
tolerance is unknown. We examined
whether baseline uric acid levels predict
incident type 2 diabetes by glucose toler-
ance status in older adults.
RESEARCH DESIGN AND
METHODS— Participants were older
adults who had an oral glucose tolerance
testanduricacidmeasuredbetween1984
and 1987. The 566 participants without
baseline diabetes by history and oral glu-
cose tolerance test were evaluated for in-
cident diabetes an average of 13 years
later (0.85 years; maximum 22 years).
Baseline glucose tolerance status was de-
ﬁned by American Diabetes Association
criteria as 1) normoglycemia (n  276):
fasting plasma glucose 100 mg/dl and
2-h postchallenge glucose 140 mg/dl;
2) impaired fasting glucose (IFG; n 
152): fasting plasma glucose 100 mg/dl
and126mg/dl;and3)impairedglucose
tolerance (IGT; n  167): 2-h postchal-
lenge glucose 140 mg/dl and 200
mg/dl.
Participants provided written in-
formed consent. The Human Research
Protection Program at the University of
California,SanDiego,approvedthestudy
protocol.
Laboratory and anthropometric data
were collected as described (5). Incident
type 2 diabetes was deﬁned as follows:
fasting blood glucose 126 mg/dl and/or
postchallenge glucose 200 mg/dl
and/or physician-prescribed medication
for type 2 diabetes. Estimated glomerular
ﬁltration rate was calculated using the
Modiﬁcation of Diet in Renal Disease for-
mula: 186  [plasma creatinine (mg/
dl)
1.154  age (years)
0.203  (1.212 if
black)  (0.742 if female)] (6).
Analyses were performed using SPSS,
version 13.1 (SPSS, Chicago, IL). The as-
sociation between uric acid and incident
type 2 diabetes was examined using mul-
tivariate regression models after adjust-
ment for potential confounding variables
(age,sex,BMI,diureticuse,andestimated
glomerular ﬁltration rate). Receiver-
operating characteristic curves were con-
structed to calculate sensitivity and
speciﬁcity of uric acid in identifying inci-
dent type 2 diabetes by glucose tolerance
status. P values 0.05 were considered
signiﬁcant.
RESULTS— Mean age at baseline was
63.3  8.6 years; 41% were men. During
follow-up, there were 55 (9.7%) new
cases of type 2 diabetes (8, 25, and 22
among normoglycemia, IFG, and IGT
groups, respectively). At baseline, partic-
ipants who developed type 2 diabetes
during the follow-up had higher BMI
(27  3.2 vs. 24.6  3.2 kg/m
2, P 
0.001), blood pressure levels (systolic:
136.8  16.1 vs. 129.4  17.7 mmHg,
P  0.003; diastolic: 80  8.5 vs. 75.7 
8.5 mmHg, P  0.001), total cholesterol/
HDL ratio (4.3  1.2 vs. 3.7  1.1, P 
0.001), and uric acid levels (6.8  1.3 vs.
5.6  1.2 mg/dl, P  0.001) compared
with those who did not develop diabetes.
Inregressionmodelsadjustedforage,
sex, BMI, diuretic use, and estimated glo-
merular ﬁltration rate, the risk for inci-
dent type 2 diabetes in the cohort overall
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crement in uric acid levels (odds ratio
[OR] 1.65, 95% CI 1.25–2.18, P 
0.001). Uric acid still predicted incident
type 2 diabetes (OR 1.63, 95% CI 1.21–
2.19, P  0.001) after including IFG
and/or IGT in the model (OR 4.7, 95% CI
2–11, P  0.001). In the same adjusted
analyses stratiﬁed by glucose status, uric
acid levels independently predicted inci-
dent type 2 diabetes among the 152 sub-
jectswhohadIFG(OR1.75,95%CI1.1–
2.9, P  0.02) but not among those with
normoglycemia (OR 2.1, 95% CI 0.93–
4.84, P  0.07) or IGT (OR 1.42, 95% CI
0.9–2.3, P  0.15). Further adjustment
for regular physical exercise, family his-
tory of type 2 diabetes, and triglyceride
levels did not materially change the
results.
Among participants with IFG, a uric
acid level 6.35 mg/dl had 80% sensitiv-
ityand70%speciﬁcitytoidentifyindivid-
uals who later developed type 2 diabetes
(area under receiver-operating character-
istic curve 0.751) (Fig. 1). The negative
predictive value of a uric acid level 5.35
mg/dl was 100%; this value was calcu-
lated using its receiver-operating charac-
teristic curve sensitivity (100%) and
speciﬁcity (40%) based on the prevalence
of diabetes in the U.S population (7). In
our sample, 30% of individuals who had
IFGalsohaduricacidlevels5.35mg/dl.
CONCLUSIONS — In this popula-
tion-based study, uric acid levels inde-
pendently predicted incident type 2
diabetes (after adjustment for variables
known to be associated with type 2 dia-
betes) only among individuals with IFG.
Theassociationofuricacidlevelsand
type 2 diabetes incidence has been re-
ported in two other populations: in a
6-year follow-up study of 2,310 Japanese
male adults, OR the odds ratio for type 2
diabetesincidenceofthehighesturicacid
quintile compared to lower quintiles was
1.63 (95% CI 1.2–2.2, P  0.001) after
adjustments for age, sex, BMI, and other
covariates(4).Thehighestquartileofuric
acid was also associated with incident
type 2 diabetes in the Rotterdam study
(4,536 adults followed for 10 years) (3).
Although these studies demonstrated an
association of uric acid with type 2 diabe-
tes incidence, neither addressed the asso-
ciation of uric acid with incident type 2
diabetes by glucose tolerance status.
Uric acid levels had high speciﬁcity
for individuals with IFG. The current rec-
ommendation is to perform an oral glu-
cosetolerancetestinindividualswithIFG
to better deﬁne the risk of type 2 diabetes
(8); but testing glucose tolerance is un-
pleasant and expensive. In this small co-
hort, a simple measurement of uric acid
5.35 mg/dl demonstrated a 100% neg-
ative predictive value of incident type 2
diabetes over a maximum 22-year follow-
up. If conﬁrmed, this simple inexpensive
test might help to identify older adults
with IFG who are at little risk for devel-
opingtype2diabetesandwouldnotneed
an oral glucose tolerance test. This obser-
vation would be important, since in the
U.S., the elderly have the greatest current
burden and expected increase in preva-
lence of type 2 diabetes (9,10).
This study has limitations. The Ran-
cho Bernardo cohort is a homogeneous
population(largelyCaucasianandmiddle
class), so results may not be generalizable
to other populations. The average age of
participants was 68 years at baseline; the
role of uric acid in predicting incident
type 2 diabetes among younger adults
needs further study. Because of the small
number of new type 2 diabetes cases, this
study had limited power to exclude
complete effectiveness of uric acid pre-
diction among IGT and normoglycemia
groups. This does not obscure the main
result, showing that uric acid adds to
the prediction of type 2 diabetes among
adults with IFG.
In conclusion, adding uric acid to
fasting blood glucose may help identify
older adults with IFG who are at low risk
ofdiabetesandwhodonotneedaglucose
tolerance test.
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Figure 1—Serum uric acid receiver-operating
characteristic curve of individuals with im-
paired fasting glucose for type 2 diabetes
incidence.
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